• news.cision.com/
  • BioArctic/
  • Invitation to presentation of BioArctic’s third quarter report for July - September 2022 on October 20 at 9.30 a.m. CET

Invitation to presentation of BioArctic’s third quarter report for July - September 2022 on October 20 at 9.30 a.m. CET

Report this content

Stockholm, Sweden, October 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)  will publish the company’s third quarter report for July – September 2022 on Thursday, October 20, 2022, at 08:00 a.m. CET.

In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on October 20, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the third quarter report for July – September 2022, followed by a Q&A-session. 
To attend, please dial-in at one of the numbers below, from:

Sweden: +46 8 519 993 83
UK: +44 333 300 0804, Pin code: 87560307#
US: +1 631 913 1422, Pin code: 87560307#
Webcast: https://tv.streamfabriken.com/bioarctic-q3-2022

The webcast will also be available on demand on BioArctic’s corporate website https://www.bioarctic.se/en/section/investors/presentations/ after the presentation.


For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations, BioArctic AB
E-mail: oskar.bosson@bioarctic.se  
Tel: + 46 704 10 71 80

This information was submitted for publication at 08:30 a.m. CET on October 14, 2022.

About BioArctic AB 
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com